Business
Starpharma hunts for cash as it speeds up COVID nasal spray treatment – Sydney Morning Herald
The Melbourne biotech is in a trading halt as it launches a placement for a COVID treatment it hopes to be ready by next year.
Starpharma shares have been on a tear over the past month since the business started to update the market on progress about the nasal spray. Shares have jumped from $1.41 to $1.60 over the past month.
The nasal spray repurposes Starpharma’s antiviral product SPL7013, which is already used in its sexual health products including condoms. The company hopes the compound will bind to the SARS-COV-2 spike protein and block the virus from attaching to cells.
Earlier this month the company released d…
-
Noosa News19 hours agoBaby boy killed and woman seriously injured after major crash on M1 at Gaven, Gold Coast
-
Business17 hours agoHow to boost your superannuation in the final 10 years before retirement
-
Noosa News21 hours agoSunshine Butterflies 5th annual Walk in Wings returns to Noosa
-
Noosa News17 hours agoBec Mac wants to wake up the world’s earliest-rising city